ArticleFrontiers in cardiovascular medicine2025
Assessment of right ventricular involvement in patients with anti-MDA5 Ab+ DM: a prospectively observational study with cardiac magnetic resonance imaging.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-melanoma differentiation-associated gene 5 dermatomyositis (anti-MDA5 Ab+ DM) is characterized by amyopathic DM with interstitial lung disease. Its impact on the right ventricle remains unclear. We aim to evaluate RV involvement in anti-MDA5 Ab+ DM patients using cardiovascular magnetic resonance (CMR). Methods: This single-center, prospective cohort study included 43 anti-MDA5 Ab+ DM patients (24 males, mean age = 44.7 ± 11.1 years) and 30 age- and gender-matched healthy controls (18 males, mean age = 44.8 ± 10.4 years). All patients underwent CMR before treatment. RV functional parameters, including ejection fraction (RVEF), end-diastolic/end-systolic remodeling index (RVEDRI/RVESRI), and right ventricular long-axis strain (RV-LAS), and RV and LV T1 and T2 mapping were analyzed. Differences between the two groups were evaluated, and correlations with clinical data were explored. Results: Anti-MDA5 Ab+ DM patients exhibited a significant decrease in RVEF (45.7 ± 5.9% vs. 52.7 ± 6.6%, Conclusion: RV subclinical dysfunction is common in patients with anti-MDA5 Ab+ DM. RV parameters on CMR such as RV-LAS and RVESRI serve as valuable imaging markers for early detection and risk stratification. These findings underscore the importance of routine cardiac evaluation in anti-MDA5 Ab+ DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.